Description
Rivastigmineisaninhibitorofacetylcholinesterase(AChE)andbutylcholinesterase(BChE)thatisusedclinicallytotreatdementia.Rivastigmineexhibitsanti-cholinergic,anti-inflammatory,cognitionenhancingandneuroprotectiveactivities.Invivo,rivastigmineimprovesmemoryimpairmentinaCaMKII-dependentmanner.RivastigminealsodecreasesproductionofIL-1βinvivo.Invitro,thiscompounddisplaysbenefitagainstAlzheimer’sdisease,increasingsecretionofamyloid-β(Aβ)precursorprotein(APP)anddecreasingsecretionofAβthroughmodulationofα-secretasesignaling.
References
MoriguchiS,TagashiraH,SasakiY,etal.CaMKIIactivityisessentialforimprovementofmemory-relatedbehaviorsbychronicrivastigminetreatment.JNeuRochem.2013Oct28.[Epubaheadofprint].PMID:24164423.
BaileyJA,RayB,GreigNH,etal.RivastigminelowersAβandincreasessAPPαlevels,whichparallelelevatedsynapticMarkersandmetabolicactivityindegeneratingprimaryratneurons.PLoSOne.2011;6(7):e21954.PMID:21799757.
PollakY,GilboaA,Ben-MenachemO,etal.Acetylcholinesteraseinhibitorsreducebrainandbloodinterleukin-1betaproduction.AnnNeurol.2005May;57(5):741-5.PMID:15852394.
KrallWJ,SramekJJ,CutlerNR.Cholinesteraseinhibitors:atherapeuticstrategyforAlzheimerdisease.AnnPharmacother.1999Apr;33(4):441-50.PMID:10332536.